Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

Homoharringtonine (HHT) and imatinib have a synergistic effect in the clinical treatment of chronic myeloid leukemia (CML). The purpose of the present study was to explore the underlying mechanisms by which HHT enhanced imatinib sensitivity. K562 CML cells were treated with HHT and imatinib separate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Wei, Bin, Shi, Yuye, Lu, Xueying, Ding, Yihan, Wang, Chunling, Li, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755169/
https://www.ncbi.nlm.nih.gov/pubmed/31432109
http://dx.doi.org/10.3892/mmr.2019.10539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755169/
https://www.ncbi.nlm.nih.gov/pubmed/31432109
http://dx.doi.org/10.3892/mmr.2019.10539

Ejemplares similares